More federal regulators investigating Biogen's Alzheimer's drug
Bio Pharma Dive
FEBRUARY 4, 2022
In a regulatory filing, Biogen said the FTC and the SEC are looking for information about Aduhelm's approval and marketing, meaning the drug is now the focus of four government probes.
Let's personalize your content